Object. Recombinant adenovirus is used as a competent vector in a wide spectrum of cancer gene therapies because of its high efficiency in gene delivery. To study the feasibility of gene therapy in malignant gliomas, the authors examined the antiproliferative effect of the adenovirally transduced wild-type p53 tumor suppressor gene by using 15 different high-grade glioma cell lines.
IGH-GRADE gliomas, the most common primary malignant tumors in the adult central nervous system, are considered to be excellent candidates for gene therapy for a number of reasons: 1) the prognosis in patients with high-grade gliomas is extremely poor, even with the best combination of surgery, radiotherapy, and chemotherapy; 2) local control of the disease is critical because of the general lack of distant metastasis; 3) a stereotactic device permits accurately focused therapeutic injections; and 4) the molecular mechanisms of carcinogenesis to which gene therapy should be targeted are relatively well known. 19 Among the genetic alterations in high-grade gliomas, inactivation of the p53 tumor suppressor gene is the most prevalent (30-50%). 19, 22 Restoration of p53 function by reestablishing wild-type p53 in glioma cells seems to be a promising treatment, because p53 controls critical steps in cell cycle regulation and induction of apoptosis, 19, 22 loss of which leads to uninhibited cellular growth and immortalization.
For successful treatment using this strategy, efficient gene delivery into target cells is essential. Recombinant adenovirus has been used as a competent virus vector, providing efficient gene transduction in a wide spectrum of cancers. Although several adenovirus-based experimental gene therapies have been attempted both in vitro and in vivo, 2, 10, 12, 14, 23 it has remained unclear whether an adenovirus vector is truly capable of efficiently delivering a gene into all types of gliomas.
Adenoviral entry into target cells is a critical step in gene delivery. The process of adenovirus infection occurs in two serial steps: the adenovirus initially attaches to target cells by fiber-protein binding to its specific receptor and it is subsequently internalized by interaction of the penton base and the cell surface receptors, which are the vitronectin-binding integrins ␣v␤3 and ␣v␤5. 26, 27 The cell surface receptor responsible for adenoviral cell attachment was identified only recently, when complementary DNA encoding a 46-kD protein, the CAR, was cloned Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor as the common receptor for group C adenovirus. 3 The integrin family consists of transmembrane heterodimer proteins with one ␣ subunit and one ␤ subunit. Integrins ␣v␤3 and ␣v␤5 recognize cell-adhesion molecules that contain an Arg-Gly-Asp sequence, such as fibronectin and vitronectin. The adenoviral penton base, which is composed of five identical subunits, each containing an Arg-Gly-Asp sequence, interacts with integrins ␣v␤3 and ␣v␤5, and this process promotes internalization of adenovirus into targeted cells following viral attachment.
In this study, we analyzed the responses of 15 cell lines derived from high-grade gliomas to the growth-suppressing effect of adenovirally transduced wild-type p53. We found that the transgene expression levels varied among different cell lines tested and that expression levels corresponded with the growth-suppressing effect. Here we present the results of our analyses, in which we examined the correlation between the gene transduction efficiency, the growth-suppressing effect, and the expression levels of cell surface receptors relevant to adenoviral cell entry, namely CAR and integrins ␣v␤3 and ␣v␤5.
Materials and Methods

Cell Lines and Culture Conditions
Fifteen human glioma cell lines, 11 derived from glioblastomas multiforme and four from anaplastic astrocytomas were used in this study (Table 1 ). All cell lines were maintained using Dulbecco's modified essential medium supplemented with 0.1 mM L-glutamine, 0.1% NaHCO 3 , 100 U/ml penicillin-G, and 10% fetal calf serum, at 37°C in a humidified 5% CO 2 atmosphere.
Analysis of p53 Status by Using Yeast Functional Assay
The yeast functional assay is a slight modification of a method previously described. 6, 21 Samples of RNA were reverse transcribed at 37°C for 1 hour by using Moloney's murine leukemia virus reverse transcriptase and 25 pM p53-specific oligonucleotides: RT1 (5Ј-CGGGAGGTAGAC-3Ј). Complementary DNA was PCR amplified with recombinant Pfu polymerase and P3 and P4 primers, which are described elsewhere, 6 on a thermal cycler by using the following conditions: 95°C for 60 seconds, followed by 35 cycles of 94°C for 40 seconds, 65°C for 70 seconds, 78°C for 90 seconds, and then 78°C for 120 seconds. Satisfactory amplification was confirmed by examining the PCR product in a 1% agarose gel. The crude PCR product and linearized p53-expression vector (pSS16) were cotransfected into the yeast reporter strain (yIG397), which was plated and grown as previously described. 6 
Sequencing of DNA
Yeast digested for 1 hour by using Zymolyase 100T and plasmid was recovered using an alkaline lysis procedure in plasmid kit form and transformed into XL-1 blue Escherichia coli cells by electroporation. At least four independent yeast colonies were tested per sample. The plasmids were sequenced using a commercially available kit on an automated sequencer. The entire region tested by the functional assay (codons 53 and 364) was sequenced using the following primers: p3seq, 5Ј-ATTTGATGCTGTCCCCGGACG-ATATTGAAC-3Ј; p11seq, 5Ј-TACTCCCCTGCCCTCAACAAG-ATG-3Ј; p12seq, 5Ј-TTGCGTGTGGAGTATTTGGATGAC-3Ј; and p13seq, 5Ј-GCCCATCCTCACCATCATCACACT-3Ј.
Adenovirus-Mediated p53 Gene Transfer
The adenoviral vectors Ad-p53 and Ad-Luc were produced and titrated in a manner previously described. 7, 23 Monolayer cultures were infected with Ad-p53 expressing wild-type p53 or Ad-Luc expressing the firefly luciferase gene. The MOI was defined as the ratio of the total number of plaque-forming units used in a particular infection to the total number of glioma cells to be infected.
The MTT Assay
Approximately 5 ϫ 10 3 glioma cells in 100 l of culture medium per well were seeded into 96-well culture plates and allowed to adhere overnight. The Ad-p53 or Ad-Luc was added at serial MOIs (0, 0.6, 1.3, 2.5, 5, 10, 20, and 40) to 48 wells (eight different MOIs in six wells each). Following incubation for 4 days at 37˚C in a 5% CO 2 atmosphere, cell numbers were evaluated using the MTT assay, as previously described. 18 An average optical density was calculated on four wells, excluding the maximum and minimum values among six wells. Assay results were expressed as percentages of the average optical density in Ad-p53-treated cells to that in Ad-Luctreated cells. A reduction in cell number that was dose dependent and less than 70% at the maximum 40 MOI was regarded to be sensitive.
The p53 Quantitative ELISA
Approximately 5 ϫ 10 5 glioma cells in 5 ml of culture medium per dish were seeded into five culture dishes per cell line and allowed to adhere overnight. The Ad-p53 and Ad-Luc were then infected with serial MOIs (0, 2, and 20). The cells were harvested following incubation at 37˚C in a 5% CO 2 atmosphere for 3 days after infection and were lysed in resuspension buffer (50 mM Tris, 5 mM ethylenediamine tetraacetic acid, 0.2 mM phenylmethylsulfonate, 1 g/ml pepstatin, and 0.5 g/ml leupeptin [pH 7.4]) supplemented with antigen extraction agent. After 30 minutes of incubation on ice with occasional vortexing, the cell lysates were centrifuged and the supernatants were collected. Samples of supernatants were examined for protein concentration by using a protein assay kit and aliquots were analyzed using a p53 ELISA kit.
Luciferase Assay
Samples treated with 20 MOIs of Ad-Luc, as described in the previous section, were used for the assay. In a centrifuge tube, 20 l of each sample was added to 100 l of reconstituted luciferase assay substrate and the amount of chemiluminescence, expressed as relative light units per milligram protein, was measured in a luminometer for 10 seconds with a 5-second delay period.
Multiplex RT-PCR
Using an mRNA direct kit, mRNA was extracted from cultured cell lines. The RNA samples were reverse transcribed at 37˚C for 1 hour by using random pdN 6 primer and Moloney's murine leukemia virus reverse transcriptase. Complementary DNA was amplified using PCR with Taq-Gold polymerase and specific primers for CAR; IG␣V, IG␤3, IG␤5, and G3PDH on a thermal cycler by using the following conditions: 95˚C for 10 minutes; followed by 25 (CAR), 28 (IG␣V or IG␤3), or 30 (IG␤5) cycles of 94˚C for 40 seconds; 56˚C (CAR), 60˚C (IG␣V or IG␤3) or 58˚C (IG␤5) for 40 seconds; 72˚C for 60 seconds; and then 72˚C for 5 minutes. The PCR products were electrophoresed in 1% agarose gels and photographed using ultraviolet light. The intensity of each PCR product was quantified using image-analysis software, and relative mRNA levels were calculated as a percentage of the G3PDH control.
The oligonucleotide primers of CAR, IG␣V, IG␤3, and IG␤5 were designed on the basis of specific human complementary DNA sequences (GenBank accession numbers were as follows: CAR Y07593, IG␣V M14648, J02826, and M18365; IG␤3 M57494, M20311, M35999, and U95204; and IG␤5 M35011). The sizes of the PCR products were expected to be: CAR 302 bp; IG␣V 287 bp; IG␤3 265 bp; IG␤5 454 bp; and G3PDH 983 bp. The following primers were used: CAR-F, 5Ј-AGATAAAATGTGAACCAA-AAGAAG-3Ј; CAR-R, 5Ј-GCAAAAGATGATAAGACCAAT-GAG-3Ј; IG␣V-F, 5Ј-ACTCTTAGCTGGTCTTCGTT-3Ј; IG␣V-R, 5Ј-TTGGACCATTGTTTCTCAGC-3Ј; IG␤3-F, 5Ј-CACCAT-CCACGACCGAAAAG-3Ј; IG␤3-R, 5Ј-GACATTCTCCCAACC-TACCC-3Ј; IG␤5-F, 5Ј-GCCTATCTCCACGCACACTG-3Ј; IG␤5-R, 5Ј-AGACTCCGACCCTTCCTGAC-3Ј; G3PDH-F, 5Ј-TGAAGGTCGGAGTCAACGGATTTGGT-3Ј; and G3PDH-R, 5Ј-CATGTGGGCCATGAGGTCCACCAC-3Ј.
Antisense Oligonucleotides
The antisense oligonucleotide p53-AS, corresponding to OL(1) p53 in a previous report, 4 is complementary to a region within exon 10 of the p53 gene, and the phosphodiester backbone is replaced throughout with a phosphorothioate linkage. The sense p53-S is complementary to p53-AS: p53-AS, 5Ј-CCCTGCTCCCCCCTG-GCTCC-3Ј; and p53-S, 5Ј-GGAGCCAGGGGGGAGCAGGG-3Ј.
Sources of Supplies and Equipment
Moloney's murine leukemia virus reverse transcriptase was purchased from Gibco-BRL (Tokyo, Japan). Recombinant Pfu polymerase was obtained from Stratagene (La Jolla, CA), Zymolyase 100T from Seikagaku-Kogyo (Tokyo, Japan), and G3PDH from Clontech (Palo Alto, CA). The QIAprep plasmid kit was purchased from Qiagen (Hilden, Germany). The thermal cycler (model 2400), the Dye Deoxy Terminator kit (for plasmid sequencing), and TaqGold polymerase were obtained from Perkin-Elmer (Chiba, Japan).
The ABI 373A automated sequencer was provided by Applied Biosystems (Foster City, CA), the Pantropic p53 Rapid Format ELISA kit and antigen extraction agent by Oncogene Research Products (Cambridge, MA), and the BCA protein assay kit by Pierce (Rockford, IL). The luciferase assay system was purchased from Promega (Madison, WI), and the TD-20/20 luminometer from Turner Designs (Sunnyvale, CA). The Dynabeads mRNA direct kit was manufactured by Dynal AS (Oslo, Norway). Image-analysis software (version 1.61) was freely obtained from the National Institutes of Health (Bethesda, MD). 
Results
The p53 Status of High-Grade Glioma Cell Lines Used in This Study
Sensitivity of Glioma Cell Lines to the Adenovirally Transduced Wild-Type p53 Gene
The wild-type p53 gene was transfected using recombinant adenovirus vectors (Ad-p53) into 15 high-grade glioma cell lines (11 glioblastomas and four anaplastic astrocytomas). Adenovirus expressing the firefly luciferase gene (Ad-Luc) was also transfected into all 15 cell lines in separate wells for use as a control. To assess the growth-inhibiting effect, cell viability was evaluated using an MTT assay. Of the 10 cell lines that have mutated endogenous p53, five exhibited a dose-dependent growth inhibition (Fig. 1A) , whereas the remaining five cell lines did not demonstrate any growth retardation (Fig. 1B) . None of the five cell lines with wild-type endogenous p53 displayed growth inhibition in response to Ad-p53 administration (Fig. 1C) .
Efficiency of Adenovirally Mediated Gene Transfer and Measurement of p53 Protein Levels in Transfected Glioma Cell Lines
To quantify the efficiency of adenovirally mediated gene transfer and to measure p53 protein levels in malignant glioma cell lines, Ad-p53 and Ad-Luc were transfected at serial MOIs (0, 2, and 20). Following an incubation lasting 3 days, the cell lysates were extracted and quantified for total protein content. Gene transduction efficiency was evaluated using a luciferase assay with the sample treated with Ad-Luc at 20 MOI. The p53 protein levels of all 15 cell-line samples were also quantified using p53 quantitative ELISA. The results of both the luciferase assay and the p53 ELISA were normalized using the total protein content of each cell line.
Gene transduction efficiency was high in five cell lines that showed a high sensitivity to adenovirally transfected wild type p53 (Table 2 ). In contrast, the 10 cell lines that were resistant to administration of Ad-p53 demonstrated low gene transduction efficiencies; all but one produced a luminointensity less than 1000 relative light units/ g (Table 2 ).
In each of the five cell lines that showed a high sensitivity to adenovirus infection and to wild-type p53-mediated growth inhibition, the amount of p53 protein was increased by treatment with Ad-p53 at 20 MOI, compared with treatment with Ad-Luc and Ad-p53 at 2 or 0 MOI ( Table 2 ). The LN827 and HUG31 lines, in which p53 protein was not detected at 0 MOI, demonstrated a slight increase in the p53 protein level at 20 MOI of Ad-p53. In the 10 resistant cell lines, on the other hand, all except one demonstrated no increase in p53 protein as a result of the Ad-p53 transfer ( Table 2 ). The SF126 cell line, which showed a relatively high transduction efficiency, demonstrated a slight increase in p53 protein level at 20 MOI of Ad-p53.
Correlation Between Expression Levels of CAR, IG␣V, IG␤3, and IG␤5, and the Susceptibility of Glioma Cells to Adenovirus Vector
To see whether molecules relating to cellular incorporation of adenovirus determine the sensitivity of glioma cells to adenovirus-mediated wild-type p53 gene transfer, we examined mRNA expression levels of CAR, which is the primary receptor for adenovirus, and those of integrins ␣v␤3 and ␣v␤5, which mediate virus internalization, by semiquantitative multiplex RT-PCR in which G3PDH was used as an internal control.
The CAR mRNA levels in the five sensitive cell lines were high, whereas those in the 10 resistant cell lines were generally low (Fig. 2A) . These results paralleled the levels of adenovirally mediated gene transduction efficiency assessed using the luciferase assay and the antiproliferative effect assessed using the MTT assay. Two Ad-p53-resistant cell lines, LN235 and HUG27, showed relatively high CAR expressions, although the expression was lower than that in sensitive cell lines.
The mRNA levels in IG␣V, IG␤3, and IG␤5 were generally high except in two cell lines, SF295 and LN319, demonstrating no obvious correlation with the transduction efficiency or with the growth-suppressing effect in the cell lines studied (Fig. 2B) .
Changes in CAR Expression Level Dependent on p53 Status
Because of the trend that CAR expression is high in cell lines with mutated p53 and low in cell lines with wild-type p53, we tested whether p53 regulates the expression level of CAR. We transfected Ad-p53 and Ad-Luc of 20 MOI into U251MG cells (3.2 ϫ 10 6 ), which contained homozygously mutated p53. After 24, 48, and 72 hours of incubation, the mRNAs were extracted and subjected to a semiquantitative multiplex RT-PCR using CAR-specific primers and G3PDH primers as an internal control. As shown in Fig. 3A , CAR expression decreased over time after infection of Ad-p53. Although the expression level was also reduced in the Ad-Luc control, the reduction was more prominent in cells transduced with the wildtype p53 gene.
We then treated LN443 cells, which contained endogenous wild-type p53 and expressed CAR at a low level, with 5 M of p53-antisense and -sense oligomers to see whether p53 inactivation by the antisense oligomer can release repression of CAR expression. After 24, 48, and 72 hours of incubation, the mRNAs were extracted and multiplex RT-PCR was performed. Compared with cells treated with the control p53-sense oligomer, the expression of CAR was higher in cells treated with the p53-antisense oligomer (Fig. 3B) . 
Discussion
Although an efficient transgene expression is critical for successful gene therapy, the efficiency of adenoviral gene transduction in gliomas has not been systematically investigated. Recent experiments demonstrated a remarkable effect of adenovirally mediated p53 gene transduction into glioma cells in vitro and/or in vivo in animals. 2, 10, 12, 14 Note, however, that in some cell lines, a low efficiency in gene transduction and no growth alteration even at high MOIs have been demonstrated. 10, 12 Our study in which 15 different human malignant glioma cell lines were used clearly demonstrated that an efficient adenovirus-mediated gene transfer could be achieved in only a fraction of the cell lines (five of 10), which contained mutant p53 genes. None of the five cell lines with wild-type p53 could be infected by the adenovirus. The growth-inhibiting effect of the wild-type p53 gene transduction appeared to be solely dependent on the infectability of the cell lines tested. In support of this, Van Meir, et al., 25 observed that retrovirally transduced wildtype p53 induced a growth-suppression and morphological change in the LNZ308 cell line, which in our study was resistant to Ad-p53. The infectability of the cell lines closely correlated with the expression level of the primary adenovirus receptor CAR, 3 but not with the cooperative molecule integrins ␣v␤3 and ␣v␤5. 26, 27 Similar results in agreement with our data have recently been reported in lymphocytes, melanoma, and bladder cancer cells. 11, 13, 15 Only one exception in our results, LN235 cells, which were resistant to Ad-p53, in spite of the relatively high expression levels of CAR and integrins, might still have an unknown mechanism that blocks viral transcription.
In contrast to CAR, the expression levels of the integrins ␣v␤3 and ␣v␤5, which were generally high, seemed not to influence adenovirus infectability in malignant glioma cells. Human gliomas are locally invasive to surrounding normal brain tissue, and many kinds of integrins are known to participate in the biological attributes of glioma cell migration and invasion. 8, 9, 20 One of these integrins, integrin ␣v␤3, is known to overexpress in high-grade glioma cells and to confer invasiveness. 9 Our results of generally high expression of vitronectin-binding integrins were consistent with this biological feature of glioma cells. Takayama and colleagues 24 reported a different result from ours in their analysis of 15 different human lung cancer cells, in which they found a correlation between the expression levels of integrin ␣v␤5 and the susceptibility to adenovirus-mediated gene transfer.
The cellular regulatory mechanisms of CAR expression have been totally unknown. Because high expression of the CAR gene was limited to cell lines with mutated p53 and because all cell lines with wild-type p53 demonstrated low-level expression, we suspected that CAR expression might be dependent on cellular p53 status. In support of this idea, wild-type p53 transduction reduced CAR expression in U251MG cells (Fig. 3A) . Inversely, the antisense inhibition of p53 increased CAR expression two-to threefold, compared with the control sense oligomer treatment (Fig. 3B) . These results strongly suggest that wildtype p53 represses the expression of CAR and that its inactivation by mutation releases the repression. Li, et al., 15 in their recent investigation of bladder cancer cells, suggested that transcriptional regulation of the CAR gene may account for the difference in CAR protein levels. Although a detailed promoter analysis of the CAR gene is needed, the transcriptional repression of the CAR gene by p53 might be one of the known direct or indirect mechanisms. 1, 16, 17 This regulation is especially interesting in the context that adenovirus can suppress p53 function 28 and p53 can block adenovirus transcription. 5 
Conclusions
Results of this study indicate that CAR expression is a crucial determinant of transduction efficiencies in adenovirus-based gene therapy for human malignant gliomas. The evaluation of CAR expression will be important in using adenovirus for clinical application of gene therapy. The release of CAR repression by an antisense strategy or other means may provide a supportive adjuvant therapy, especially when it is achieved in a tumor cell-specific manner. 
